Carcinoma Overexpression and Overactivation of Akt in Thyroid Updated
暂无分享,去创建一个
M. Saji | M. Ringel | K. Burman | V. Bernet | L. Kohn | H. Burch | J. Saito | B. Saunier | Frank Schuppert | Nicole Hayre
[1] G. D. Vita,et al. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. , 2000, Cancer research.
[2] G. Viglietto,et al. Akt/protein kinase B promotes survival and hormone-independent proliferation of thyroid cells in the absence of dedifferentiating and transforming effects. , 2000, Cancer research.
[3] Domenico Coppola,et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer , 2000, Oncogene.
[4] C. Marshall,et al. PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS , 2000, Oncogene.
[5] J. Meinkoth,et al. Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation , 2000, Oncogene.
[6] M. Billaud,et al. Transforming Ability of MEN2A-RET Requires Activation of the Phosphatidylinositol 3-Kinase/AKT Signaling Pathway* , 2000, The Journal of Biological Chemistry.
[7] L. Schriml,et al. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. , 1999, Journal of the National Cancer Institute.
[8] L. Mulligan,et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. , 1999, The American journal of pathology.
[9] J. Wesselink,et al. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. , 1999, European journal of biochemistry.
[10] V. Yong,et al. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. , 1999, European journal of biochemistry.
[11] W. Liu,et al. Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines* , 1999, The Journal of Biological Chemistry.
[12] W. Yung,et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. , 1999, Cancer research.
[13] J. Downward,et al. Role of Phosphoinositide 3-Kinase in Activation of Ras and Mitogen-Activated Protein Kinase by Epidermal Growth Factor , 1999, Molecular and Cellular Biology.
[14] H. Wu,et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Weigel,et al. Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. , 1999, Biochemical and biophysical research communications.
[16] L. Cantley,et al. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Ritz,et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. , 1999, Human molecular genetics.
[18] S. Filetti,et al. Functional insulin receptors are overexpressed in thyroid tumors , 1999, Cancer.
[19] C. Sawyers,et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[20] J. Jen,et al. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors , 1998, Genes, chromosomes & cancer.
[21] José Luis de la Pompa,et al. Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.
[22] P. Ladenson,et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. , 1998, Cancer.
[23] S. Nicosia,et al. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. , 1998, Cancer research.
[24] M. Santoro,et al. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret , 1998, Oncogene.
[25] J. Franklyn,et al. Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia. , 1998, The Journal of clinical endocrinology and metabolism.
[26] Shunhua Xing,et al. Signal Transduction Pathways Activated by RET Oncoproteins in PC12 Pheochromocytoma Cells* , 1998, The Journal of Biological Chemistry.
[27] J. Cheng,et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas , 1998, Molecular carcinogenesis.
[28] J. Figge,et al. The ret/PTC1 rearrangement is a common feature of Chernobyl-associated papillary thyroid carcinomas from Belarus. , 1998, Thyroid : official journal of the American Thyroid Association.
[29] G. Chiappetta,et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] C. Larsson,et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. , 1997, Cancer research.
[31] C. Eng,et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome , 1997, Nature Genetics.
[32] J. Cheng,et al. Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis , 1997, Oncogene.
[33] M. Ivan,et al. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells , 1997, Oncogene.
[34] Jing Li,et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.
[35] G. Botti,et al. Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene. , 1996, Oncogene.
[36] P. Ladenson,et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. , 1996, Archives of internal medicine.
[37] Y. Hayashizaki,et al. Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. , 1996, Biochemical and biophysical research communications.
[38] M. Ivan,et al. Mitogenic stimulation of normal and oncogene-transformed human thyroid epithelial cells by hepatocyte growth factor , 1996, Molecular and Cellular Endocrinology.
[39] J. Cheng,et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.
[40] Michael J. Fry,et al. Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.
[41] Kunihiko Ito,et al. Increased Activity of Insulin‐like Growth Factor‐binding Protein in Human Thyroid Papillary Cancer Tissue , 1994, Japanese journal of cancer research : Gann.
[42] T. Ushijima,et al. Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. , 1993, British Journal of Cancer.
[43] M. Pierotti,et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. , 1992, Oncogene.
[44] J. Cheng,et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[45] L. Deftos,et al. Multiple hamartoma syndrome (Cowden's disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma). , 1992, American journal of clinical pathology.
[46] J. Fagin,et al. Allelotype of human thyroid tumors: loss of chromosome 11q13 sequences in follicular neoplasms. , 1991, Molecular endocrinology.
[47] S. Rubin,et al. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. , 1990, Molecular endocrinology.
[48] M. Santoro,et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.
[49] Kunihiko Ito,et al. Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. , 1989, Acta endocrinologica.
[50] S. Staal. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[51] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[52] C. Eng. RET proto-oncogene in the development of human cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] A. Fusco,et al. Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: comparison with FRTL-5 cells. , 1999, European journal of endocrinology.
[54] J. Sagartz,et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. , 1996, Endocrinology.
[55] J. Fagin,et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. , 1993, The Journal of clinical investigation.
[56] B. Estour,et al. Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1) , 1989, Virchows Archiv. B, Cell pathology including molecular pathology.